The analysis of the relationship between ICDRS and therapeutic sensitivity to anti-PD-L1 treatment was constrained by the limited availability of data from CRC patients undergoing immune checkpoint blockade (ICB) therapy. The gene discussed is CD274; the disease is colorectal carcinoma.